Form 8-K - Current report:
SEC Accession No. 0001390478-18-000013
Filing Date
2018-05-24
Accepted
2018-05-24 16:29:55
Documents
3
Period of Report
2018-05-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sls-20180524x8xklicenseagr.htm 8-K 41737
2 EXHIBIT 10.1 slsexhibit20180524-101.htm EX-10.1 108473
3 EXHIBIT 10.2 slsexhibit2018054-102.htm EX-10.2 28851
  Complete submission text file 0001390478-18-000013.txt   180699
Mailing Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017
Business Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017 (813) 864-4523
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 18858232
SIC: 2834 Pharmaceutical Preparations